Preclinical anticancer studies on the ethyl acetate leaf extracts of Datura stramonium and Datura inoxia

Nasir, Bakht; Baig, Muhammad Waleed; Majid, Muhammad; Ali, Syeda Masooma; Khan, Muhammad Zafar Irshad; Kazmi, Syeda Tayyaba Batool; Haq, Ihsan-ul

doi:10.1186/s12906-020-02975-8

BMC Complementary Medicine and Therapies

Table 10 Percent alleviative effects of DSL-EA and DIL-EA extracts in benzene induced leukemia

From: Preclinical anticancer studies on the ethyl acetate leaf extracts of Datura stramonium and Datura inoxia

Evaluation parameters	Study Groups
	Disease control	Positive control	DSL-LD (P)	DSL-HD (P)	DIL LD (P)	DIL HD (P)	DSL HD (T)	DIL HD (T)
	Disease control	Percent alleviative effect
Haematalogical parameters
RBCs (×10⁶)/μl	4.33 ± 0.065	41.80 ± 2.20^a	32.90 ± 1.65^c	38.71 ± 1.92^ab	35.64 ± 0.85^bc	39.66 ± 1.51^ab	23.79 ± 1.62^d	32.74 ± 1.88^c
WBCs (×10³) /μl	7.78 ± 0.012	50.53 ± 0.87^b	53.54 ± 0.33^a	52.14 ± %0.49^a	50.39 ± 0.35^b	48.46 ± 0.15^c	45.67 ± 0.57^d	45.28 ± 0.46^d
Platelets (×10³)/μl	344 ± 3.19	44.08 ± 0.79^e	56.42 ± 0.58^b	61.81 ± 0.75^a	52.37 ± 0.89^c	58.15 ± 0.76^b	49.76 ± 0.58^d	45.25 ± 0.86^e
Endogenous antioxidant enzymes
CAT (U/min)	0.5 ± 0.04	342.67 ± 8.33^b	84.67 ± 15.53^d	100 ± 1.20^d	274 ± 12.49^c	285.3 ± 27.15^c	315.3 ± 17.47^bc	410 ± 30.27^a
POD (U/min)	1 ± 0.04	209 ± 6.56^b	70.33 ± 2.52^e	122 ± 1.73^d	63.33 ± 4.16^e	317.67 ± 3.21^a	183.67 ± 9.07^c	301 ± 10.15^a
SOD (U/mg protein)	0.96 ± 0.05	261.81 ± 3.66^a	154.17 ± 2.08^e	198.96 ± 4.17^c	190.63 ± 2.08^cd	232.29 ± 3.76^b	176.7 ± 10.43^d	191.6 ± 10.26^cd
GST (nM/min/ml)	81.01 ± 0.44	191 ± 1.81^b	33.72 ± 0.78^e	99.22 ± 0.87^c	34.43 ± 1.28^e	266.29 ± 1.98^a	67.07 ± 0.78^d	101.08 ± 1.91^c
Biochemical parameters
ALT (U/L)	93.20 ± 2.64	50.67 ± 2.01^b	50.83 ± 2.45^b	54.36 ± 1.92^ab	52.47 ± 1.78^ab	56.96 ± 2.43^a	58.13 ± 2.10^a	57.46 ± 1.70^a
AST (U/L)	67.80 ± 2.05	59.73 ± 0.94^bc	65.23 ± 1.50^a	61.91 ± 1.27^ab	54.72 ± 1.89^de	58.58 ± 1.39b^cd	56.96 ± 1.01^cde	53.79 ± 1.69^e
ALP (U/L)	356 ± 5.69	60.69 ± 1.01^bcd	58.38 ± 0.92^de	61.14 ± 1.14^abc	57.28 ± 0.81^e	59.43 ± 0.35^cde	62.15 ± 1.01^ab	63.38 ± 1.13^a
Urea (mg/dl)	72.2 ± 2.76	62.59 ± 1.41^a	51.01 ± 1.37^c	57.02 ± 2.44^ab	50.15 ± 1.18^c	52.29 ± 1.71^bc	61.52 ± 2.84^a	59.65 ± 2.60^a
Creatinine (mg/dl)	2.89 ± 0.45	61.01 ± 5.04^a	60.21 ± 3.34^a	61.82 ± 4.19^a	60.32 ± 3.89^a	62.40 ± 2.78^a	61.25 ± 3.51^a	61.94 ± 2.50^a
Bilirubin (mg/ml)	7.56 ± 0.97	65.21 ± 2.82^a	58.38 ± 1.23^a	63.10 ± 8.54^a	59.79 ± 4.37^a	60.76 ± 3.44^a	68.17 ± 1.07^a	68.08 ± 5.16^a
Total proteins (g/dl)	2.14 ± 0.11	214.02 ± 18.19^a	185.51 ± 23.36^a	224.45 ± 27.63^a	213.55 ± 29.55^a	210.28 ± 23.22^a	186.29 ± 17.50^a	195.02 ± 19.61^a
Lipid peroxidation assay
TBARs (nM/min/mg protein)	133.7 ± 2.61	35.74 ± 0.82^a	15.08 ± 1.65^d	24.27 ± 1.11^c	15.12 ± 1.74^d	21.39 ± 1.22^c	37.41 ± 0.89^a	31.01 ± 1.32^b

Results of disease control are expressed as mean ± SD (n = 6, where n = number of rats analysed in each group). Alleviative effects of remaining groups are expressed as percent increase or decrease (bold) of tested parameters in comparison to the disease control group. Groups are compared statistically to the positive control group and superscripts (a-e) in individual rows specifying significance at p < 0.05

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com